1026530-91-5

Basic information

• Product Name: 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-N-pyridin-4-yl-nicotinamide
• CAS NO: 1026530-91-5
• Molecular Weight: 457.553
• Mol File: 1026530-91-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-N-pyridin-4-yl-nicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-N-pyridin-4-yl-nicotinamide(1026530-91-5)
• EPA Substance Registry System: 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-N-pyridin-4-yl-nicotinamide(1026530-91-5)

Safety Data

• Hazardous Substances Data: 1026530-91-5(Hazardous Substances Data)

Upstream product

• 181823-88-1 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-nicotinic acid 
• 114719-65-2 (2,4-dimethoxyphenyl)methanethiol 
• 69750-01-2 2-chloro-6-phenylpyridine-3-carboxylic acid 
• 504-24-5 4-aminopyridine 
• 1026333-99-2 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-nicotinoyl chloride 

Relevant articles and documents

Nicotinamide derivatives as a new class of gastric (H+/K+)-ATPase inhibitors. II. Synthesis and structure-activity relationships of 2-[(2,4- dimethoxyhenzyl)sulfinyl]-N-(4-pyridinyl)pyridine-3-carboxamides

Members of a new series of 2-[(2,4-dimethoxybenzyl)sulfinyl]-N-(4- pyridinyl)pyridine-3-carboxamides were synthesized and evaluated for their gastric antisecretory activity and the ability to inhibit cytochrome P450- dependent O-dealkylation of 7-ethoxycoumarin (7-EC) in rat liver microsomes. Several of the compounds synthesized exhibited potent inhibitory activities against both [14C]aminopyrine accumulation stimulated by dibutyryl cyclic AMP in isolated rabbit parietal cells and histamine-induced gastric acid secretion in pylorus-ligated rats when administered intraduodenally; their inhibitory activities were equivalent to or superior to those of the parent compound [2[(2,4-dimethoxybenzyl)sulfinyl]-N-(4-pyridinyl)pyridine-3- carboxamide] and omeprazole. Among the compounds having potent antisecretory activity in vitro and in vivo, 2-[(2,4-dimethoxybenzyl)sulfinyl]-N-(2,5- dimethyl-4-pyridinyl)pyridine-3-carboxamide and 2-[(2,4- dimethoxybenzyl)sulfinyl]-N-(2,6-dimethyl-4-pyridinyl)pyridine-3-carboxamide in particular showed lower inhibitory activity against the 7-EC deethylase than omeprazole. It seems probable that, unlike omeprazole, these compounds do not interact with a metabolism of other drugs in vivo. These compounds, therefore, are considered to be more promising candidate agents for treating acid-related gastrointestinal disorders than the parent compound reported previously.